title: Fifteen-year experience with the mitral Carpentier-Edwards PERIMOUNT pericardial bioprosthesis.
abstract: BACKGROUND
  This multicenter study concerning the mitral PERIMOUNT valve previously reported clinical results at 12 years; this report updates the performance to 15 years postoperatively.
  
  
  METHODS
  The 435 patients (mean age 60.7+/-11.6 years; 41.1% male) underwent implantation with the PERIMOUNT valve between 1984 and 1989 at seven institutions. Follow-up was complete for 96.1% of the cohort. The mean follow-up was 8.1+/-4.4 years (range 0 to 15.4 years) for a total of 3492 patient-years.
  
  
  RESULTS
  There were 34 (7.8%) operative deaths, one (0.2%) valve related. The late mortality rate was 5.3%/patient-year (2.2%/patient-year valve related). At 14 years, the overall actuarial survival rate was 37.1%+/-3.3% (63.1%+/-4.4% valve related). Actuarial freedom from complications at 14 years was as follows: thromboembolism, 83.8%+/-3.2% (1.1%/patient-year); hemorrhage, 86.6%+/-3.2% (1.1%/patient-year); and explant due to structural valve deterioration (SVD), 68.8%+/-4.7%. Actual freedom from explant due to SVD was 83.4%+/-2.3%. Rates of structural failure decreased with increasing age at implant.
  
  
  CONCLUSIONS
  The Carpentier-Edwards PERIMOUNT Pericardial Bioprosthesis is a reliable choice for a tissue valve in the mitral position, especially in patients more than 60 years of age.
authors.affiliation: Department of Cardiothoracic Surgery and Cardiology, Hĵpital Trousseau and Francois Rabelais University, Tours, France. marchand@med.univ-tours.fr
authors.forename: M A
authors.initials: MA
authors.lastname: Marchand
authors.forename: M R
authors.initials: MR
authors.lastname: Aupart
authors.forename: R
authors.initials: R
authors.lastname: Norton
authors.forename: I R
authors.initials: IR
authors.lastname: Goldsmith
authors.forename: L C
authors.initials: LC
authors.lastname: Pelletier
authors.forename: M
authors.initials: M
authors.lastname: Pellerin
authors.forename: T
authors.initials: T
authors.lastname: Dubiel
authors.forename: W J
authors.initials: WJ
authors.lastname: Daenen
authors.forename: P
authors.initials: P
authors.lastname: Herijgers
authors.forename: F P
authors.initials: FP
authors.lastname: Casselman
authors.forename: M P
authors.initials: MP
authors.lastname: Holden
authors.forename: T E
authors.initials: TE
authors.lastname: David
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001705:Bioprosthesis; D002423:Cause of Death; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery*; D011183:Postoperative Complications / Q000401:mortality; D011474:Prosthesis Design; D011475:Prosthesis Failure; D012307:Risk Factors